Commerce looks into Vioxx
This article was originally published in The Tan Sheet
Executive Summary
The House Energy & Commerce committee is investigating allegations by FDA Office of Drug Safety Associate Director for Science David Graham, MD, that he was pressured to "water down" his conclusions on Vioxx safety, as part of a broad inquiry into events surrounding the drug's withdrawal. Committee Chair Joe Barton (R- Texas) and Ranking Member John Dingell (D-Mich.) pose a series of questions about clinical trial data and conduct at Merck and FDA in Nov. 23 letters to Acting Commissioner Lester Crawford, PhD, and Merck Chairman Raymond Gilmartin...